Tysabri Market, By Indication (Multiple Sclerosis (MS) and Crohns Disease (CD)), By End User (Hospitals, Specialty Clinics, Infusion Centers, and Others (Outpatient Settings, etc.)), and By Geography (North America, Latin America, Europe, Asia Pacific, Mi

The Global Tysabri Market is estimated to be valued at USD 1,572.7 Mn in 2025 and is expected to reach USD 1,120.3 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of -4.7% from 2025 to 2032.

The global Tysabri market, a key treatment for relapsing forms of multiple sclerosis (MS) and Crohn’s disease, is witnessing slow growth with a negative CAGR. While the drug’s effectiveness in reducing relapse rates and disability progression remains significant, safety concerns, particularly the risk of progressive multifocal leukoencephalopathy (PML), continue to pose challenges. This has led to increased monitoring requirements for patients, which combined with the rising availability of alternative therapies, has slowed market expansion.

The market dynamics are further impacted by increasing competition from newer treatments, including oral medications, that offer more convenience and fewer safety risks. Despite Tysabri's proven efficacy, the shift towards alternative treatments and a growing preference for less invasive therapies have led to a deceleration in market growth. Ongoing clinical research into dosing strategies and combination therapies aims to optimize Tysabri's use, but the overall market trajectory is expected to remain slow with limited future growth potential.

Market Dynamics:

The global Tysabri market, once driven by key factors such as the rising global prevalence of multiple sclerosis (MS), now faces slower growth, reflected in a negative CAGR. In November 2020, according to National Library of Medicine, MS affects approximately 2.8 million people worldwide, with incidence rates increasing in developed nations due to improved diagnostic techniques and heightened awareness among healthcare professionals. While Tysabri has demonstrated clinical efficacy in reducing relapse rates by up to 68% and disability progression by 42%, its market dominance is under pressure. The growing preference for oral disease-modifying therapies and next-generation monoclonal antibodies, offering improved safety profiles and convenience, is contributing to market share erosion.

Despite these challenges, there are still some opportunities for Tysabri. The increasing use of personalized medicine and biomarker-guided therapy selection, such as JC virus antibody testing and risk stratification, continues to improve patient safety profiles. Additionally, extended interval dosing protocols and companion diagnostics present potential avenues to optimize treatment, while geographic expansion into emerging markets with improving healthcare infrastructure may offer limited growth opportunities. However, overall market growth remains slow, and the negative CAGR suggests that the market will face continued pressure in the coming years.

Key Features of the Study:

• This report provides in-depth analysis of the global Tysabri market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Tysabri market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key company covered as a part of this study include Biogen Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global Tysabri market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Tysabri market

Market Segmentation

• Indication Insights (Revenue, USD Mn, 2020 - 2032)
• Multiple Sclerosis (MS)
• Crohn’s Disease (CD)
• End User Insights (Revenue, USD Mn, 2020 - 2032)
• Hospitals
• Specialty Clinics
• Infusion centers
• Others (Outpatient Settings, etc.)
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Biogen

Show more